Abstract:
Antimicrobial susceptibility testing (AST) of human mycoplasmas using microdilution is time-consuming. In this study, we compared the performance of MICRONAUT-S plates (Biocentric-Bruker) designed for AST of Ureaplasma parvum, Ureaplasma urealyticum, and Mycoplasma hominis with the results using the Clinical & Laboratory Standards Institute (CLSI) reference method. Then, we investigated the prevalence and mechanisms of resistance to tetracyclines, fluoroquinolones, and macrolides in France in 2020 and 2021. The two methods were compared using 60 strains. For the resistance prevalence study, U. parvum-, U. urealyticum-, and M. hominis-positive clinical specimens were collected for 1 month each year in 22 French diagnostic laboratories. MICs were determined using the MICRONAUT-S plates. The tet(M) gene was screened using PCR, and fluoroquinolone resistance-associated mutations were screened using PCR and Sanger sequencing. Comparing the methods, 99.5% (679/680) MICs obtained using the MICRONAUT-S plates concurred with those obtained using the CLSI reference method. For 90 M. hominis isolates, the tetracycline, levofloxacin, and moxifloxacin resistance rates were 11.1%, 2.2%, and 2.2%, respectively, with no clindamycin resistance. For 248 U. parvum isolates, the levofloxacin and moxifloxacin resistance rates were 5.2% and 0.8%, respectively; they were 2.9% and 1.5% in 68 U. urealyticum isolates. Tetracycline resistance in U. urealyticum (11.8%) was significantly (P < 0.001) higher than in U. parvum (1.2%). No macrolide resistance was observed. Overall, the customized MICRONAUT-S plates are a reliable, convenient tool for AST of human mycoplasmas. Tetracycline and fluoroquinolone resistance remain limited in France. However, the prevalence of levofloxacin and moxifloxacin resistance has increased significantly in Ureaplasma spp. from 2010 to 2015 and requires monitoring.
OBJECTIVE: Antimicrobial susceptibility testing of human urogenital mycoplasmas using the CLSI reference broth microdilution method is time-consuming and requires the laborious preparation of antimicrobial stock solutions. Here, we validated the use of reliable, convenient plates designed for antimicrobial susceptibility testing that allows the simultaneous determination of the MICs of eight antibiotics of interest. We then investigated the prevalence and mechanisms of resistance of each of these bacteria to tetracyclines, fluoroquinolones, and macrolides in France in 2020 and 2021. We showed that the prevalence of levofloxacin and moxifloxacin resistance has increased significantly in Ureaplasma spp. from 2010 to 2015 and requires ongoing monitoring.
摘要:
使用微量稀释的人支原体的抗菌素敏感性测试(AST)是耗时的。在这项研究中,我们比较了MICRONAUT-S板(Biocentric-Bruker)的性能,解脲脲原体,和人型支原体,结果使用临床和实验室标准研究所(CLSI)参考方法。然后,我们调查了四环素耐药的流行和机制,氟喹诺酮类药物,2020年和2021年法国的大环内酯类药物。使用60个菌株对两种方法进行比较。对于耐药性患病率研究,U.parv-,U.尿素-,每年在22个法国诊断实验室收集1个月的人型支原体阳性临床标本。使用MICRONAUT-S板测定MIC。用PCR方法筛选tet(M)基因,使用PCR和Sanger测序筛选与氟喹诺酮耐药相关的突变。比较方法,使用MICRONAUT-S板获得的99.5%(679/680)MIC与使用CLSI参考方法获得的一致。对于90株人源分离株,四环素,左氧氟沙星,莫西沙星耐药率为11.1%,2.2%,和2.2%,分别,没有克林霉素耐药性。对于248个U.parvum分离株,左氧氟沙星和莫西沙星耐药率分别为5.2%和0.8%,分别为68株解脲U.U.脲原体分离株的2.9%和1.5%。解脲支原体对四环素的耐药率(11.8%)显著高于(P<0.001);没有观察到大环内酯耐药性。总的来说,定制的MICRONAUT-S板是一个可靠的,人支原体AST的方便工具。法国对四环素和氟喹诺酮的耐药性仍然有限。然而,在脲原体属中,左氧氟沙星和莫西沙星耐药率显著增加.从2010年到2015年,需要监测。
目的:使用CLSI参考肉汤微量稀释法对人泌尿生殖道支原体进行抗菌药物敏感性试验耗时,需要费力地制备抗菌原液。这里,我们验证了可靠的使用,设计用于抗菌药物敏感性测试的方便板,可以同时测定八种感兴趣的抗生素的MIC。然后,我们调查了这些细菌对四环素的耐药性和机制,氟喹诺酮类药物,2020年和2021年法国的大环内酯类药物。我们表明,脲原体对左氧氟沙星和莫西沙星的耐药性显着增加。从2010年到2015年,需要持续监测。